U.S., Nov. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07917819) titled 'Low Dose Versus Standard Dose Albumin' on Oct. 19.
Brief Summary: Background:
Liver cirrhosis with ascites is a major health problem, and large-volume paracentesis (LVP) is commonly performed for management of tense or refractory ascites. However, LVP is associated with paracentesis-induced circulatory dysfunction (PICD), which can lead to renal impairment, hyponatremia, rapid recurrence of ascites, and increased mortality. Human albumin is the most effective plasma expander for prevention of PICD, but its high cost limits its use in resource-limited settings like Bangladesh.
Objective:
To compare the effectiveness of low-dose alb...